Multiple Myeloma (MM) is a plasma cell malignancy occurring in the bone marrow. The treatment of MM is dominated by stem cell transplants, immunomodulators (IMiDs), proteasome inhibitors, and CD38 monoclonal antibodies. However, the development of BCMA-targeted agents has accelerated in recent years, especially in the form of CARTs, bispecifics, and ADCs. The first BCMA-targeted therapy, belantamab mafodotin-blmf, was approved in 2020. These new agents will likely reshape the treatment landscape for R/R MM, and perhaps ND MM as well.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Multiple Myeloma to help guide strategic and tactical commercial development decisions for market participants.